Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.

Biologics

uniQure biopharma B.V., Department of Research and Development, Amsterdam, the Netherlands.

Published: September 2022

Huntington's disease is a devastating heritable neurodegenerative disorder that is caused by the presence of a trinucleotide CAG repeat expansion in the gene, leading to a polyglutamine tract in the protein. Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein. In this review, we summarize the current knowledge on the production and toxicity of N-terminal Huntingtin protein fragments. Further, we expand on various therapeutic strategies targeting N-terminal Huntingtin on the protein, RNA and DNA level. Finally, we compare the therapeutic approaches that are clinically most advanced, including those that do not target N-terminal Huntingtin, discussing differences in mode of action and translational applicability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532260PMC
http://dx.doi.org/10.2147/BTT.S270657DOI Listing

Publication Analysis

Top Keywords

n-terminal huntingtin
20
huntingtin protein
12
huntington's disease
8
protein fragments
8
huntingtin
6
n-terminal
5
protein
5
emerging therapies
4
therapies huntington's
4
disease focus
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!